Susquehanna International Group, LLP Chinook Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $1.45 Million - $2.99 Million	77,479 Added 98.43%	156,194 $6 Million
Q1 2023 May 16, 2023	BUY	$21.53 - $26.8 $1.11 Million - $1.38 Million	51,432 Added 188.51%	78,715 $1.82 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $489,726 - $718,949	-26,287 Reduced 49.07%	27,283 $714,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $938,010 - $1.25 Million	53,570 New	53,570 $1.05 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $136,451 - $189,464	-11,352 Reduced 30.04%	26,435 $432,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $116,435 - $183,312	10,892 Added 40.5%	37,787 $616,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $163,725 - $211,561	14,237 Added 112.47%	26,895 $343,000
Q2 2021 Aug 11, 2021	SELL	$13.6 - $18.98 $182,362 - $254,502	-13,409 Reduced 51.44%	12,658 $179,000
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $34,022 - $45,883	-2,401 Reduced 8.43%	26,067 $405,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $338,769 - $595,265	28,468 New	28,468 $452,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.